About
Introducing GeNiner
Seoul National University’s
First Faculty-Led Biotech Spin-off
Launched as the first faculty-led spin-off under Seoul National University’s Industry-Academic Cooperation Foundation, GeNiner is advancing into the global biopharmaceutical market through proprietary gene design technology.
Gene Design-Based Biopharmaceutical Materials
GeNiner advances gene design technology that reduces pathogen virulence while enhancing immunogenicity and stability, delivering high-performance biopharmaceutical materials.
Vision
Toward the 2029 IPO
Technology Transfer
Virus (avian coronavirus, 2022) and bacterial (Salmonella gene knockout,
2024) technology transfer of vaccine strains
Clinical Trials
AIV · IBV technology transfer and clinical trials (2025–)
Commercialization
Product approval/sales of transferred technologies · Global corporate technology transfer · Biopharmaceutical materials production (2026–)
IPO
Targeting a KOSDAQ Listing (2029)
Starting from the first technology transfer in 2022, GeNiner targets KRW 10 billion
(approx. USD 7–8M) in revenue and a KOSDAQ listing by 2029.
From technology transfer to global commercialization
— a phased growth roadmap
GeNiner develops next-generation vaccines that are safer and more production-efficient through a Reverse Genetics platform that redesigns pathogen genes to optimize antigens.
Enhanced Safety
Selectively eliminates pathogenic genes to reduce pathogenicity and improve biosafety of vaccine candidates
High Replication Efficiency
Designs recombinant vaccine strains with high replication efficiency in egg and cell culture systems
High Immunogenicity
Maximizes induction of neutralizing antibodies through antigen epitope optimization
Genetic Stability
Minimizes mutation risks to ensure stable vaccine efficacy
Core Technology
Vaccine Strain Development Platform Based on Antigen Gene Optimization-Based Vaccine Strain Development Platform
권혁준·대표이사
Hyuk-Jun Kwon
CEO
- Ph.D. in Veterinary Microbiology,
Seoul National University
- Professor of Production Animal Medicine
(Avian Medicine), College of Veterinary
Medicine, SNU
- Principal inventor of vaccines against avian
influenza and fowl typhoid.
- Former Head of R&D, Intron Biotechnology;
Co-founder of Biopoa
- Overall direction of core technology
roadmap and systems design
- Ph.D. in Veterinary Microbiology,
Seoul National University
- Former Professor and Dean, Department of
Avian Diseases, College of Veterinary
Medicine, SNU
- Developed vaccines for Avian Influenza
and Newcastle Disease, and control
technologies for Highly Pathogenic
Avian Influenza (HPAI)
Jae-Hong Kim
CTO
김재홍·기술이사
Seung-Min Hong
Senior Researcher
홍승민·책임연구원
- Ph.D. in Avian Diseases, College of
Veterinary Medicine, SNU
- Post-Doc and Research Professor, College of
Veterinary Medicine, SNU
- Participated in national COVID-19 preclinical
trial data support project
- Developed cold-adapted IBV live vaccine
- Developed reverse genetics-based recombinant
IBV live vaccine
Jun-Hyun Kim
Researcher
김준현·연구원
- Ph.D. in Poultry Clinical Veterinary Medicine,
College of Veterinary Medicine, SNU
- Research on Chicken Embryo Extract (CEE)
as an FBS substitute
- Research on high-performance recombinant
antibodies
Team
Vaccine R&D Expert Group
Our Partners